Gaush Meditech Ltd

Gaush Meditech Ltd

2407.HK
Gaush Meditech LtdHK flagHong Kong Stock Exchange
4.90
HKD
-0.05
- -
724.65MMarket Cap
Gaush Meditech Ltd
2407.HK
(Hong Kong Stock Exchange)

Recent

price

4.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
7.48
6.5
13.55
12.93
9.5
9.66
9.51
Revenue per Share
-0.25
0.67
-1.99
-3.61
1.17
0.63
0.66
Basic EPS, GAAP
1.13
0.87
1.42
1.92
1.37
0.18
0.76
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-2.47
-6.05
-2.79
-3.17
-2.84
Book Value per Share
-0.67
-0.03
-18.99
3.1
3.15
2.59
2.87
Tangible Book Value per Share
148
148
96
97
148
148
145
Basic Weighted Avg Shares
1,107
962
1,298
1,254
1,406
1,428
1,380
Sales/Revenue/Turnover
17.14
20.89
21.48
21.12
19.85
15.82
10.52
Operating Margin (%)
13
12
60
66
76
82
91
Depreciation Expense
-37
99
-190
-350
174
92
96
Net Income, GAAP
1,869.47
33.94
- -
- -
30.2
42.99
20.48
Effective Tax Rate (%)
-3.35
10.33
-14.67
-27.89
12.34
6.47
6.97
Profit Margin (%)
540
-531
649
834
499
639
630
Working Capital
16
209
826
605
127
361
357
LT Debt
-70
48
-633
1,487
1,697
1,588
1,697
Total Equity
- -
21.83
- -
- -
8.45
5.71
5.29
Return on Invested Capital (%)
- -
17.39
- -
- -
92.1
64.33
116.86
Return on Capital (%)
- -
138,009.72
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-348.98%
6.85%
Free Cash Flow
- -
56.21%
315.76%
Net Income, GAAP
- -
-80.07%
4.11%
Sales/Revenue/Turnover
- -
8.38%
-3.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,406
2024
- -
- -
- -
- -
1,428
2025
- -
- -
- -
- -
1,380

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.17
2024
- -
- -
- -
- -
0.63
2025
- -
- -
- -
- -
0.66

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Gaush Meditech Ltd is a medical technology company specializing in the manufacturing and distribution of high-precision surgical instruments, orthopedic implants, and advanced medical devices. Its product portfolio includes surgical tools such as forceps, scissors, clamps; orthopedic implants like joint replacements and fixation devices; and diagnostic equipment including imaging and monitoring systems. The company serves hospitals, clinics, and healthcare providers across Asia-Pacific and other international markets. Founded in 1995, Gaush Meditech is headquartered in Hong Kong. Recent company developments include strategic partnerships with regional healthcare providers to expand its surgical instrument distribution network, and acquisitions of smaller medical device firms to enhance its product offerings in diagnostic and monitoring technologies. In the past two years, Gaush Meditech launched a new line of smart orthopedic implants with embedded sensor technology for real-time patient monitoring. These initiatives align with the company’s goal to integrate cutting-edge digital solutions into traditional medical devices, reflecting a major strategic shift towards smart healthcare technology. Gaush Meditech operates primarily in the medical device and healthcare technology industry, targeting hospitals, surgical centers, and specialty clinics. It holds a strong regional presence in Greater China, Southeast Asia, and is expanding market reach in Europe. The company maintains a mix of wholly owned subsidiaries and joint ventures to support localized manufacturing and distribution capabilities. Gaush Meditech’s comprehensive product and service offerings, coupled with recent innovations and strategic expansions, position it as a leading player in the medical technology sector with headquarters in Hong Kong since its founding in 1995.